Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study

Conclusion: This study demonstrates the safety and tolerability of clascoterone topical cream, 1% in adolescents and adults with acne vulgaris treated BID for 14 consecutive days. J Drugs Dermatol. 2019;18(6):563-568. PMID: 31251549 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31251549?dopt=Abstract

Source: Journal of Drugs in Dermatology - June 30, 2019 Category: Dermatology Tags: J Drugs Dermatol Source Type: research